W
Walter M. Stadler
Researcher at University of Chicago
Publications - 513
Citations - 37554
Walter M. Stadler is an academic researcher from University of Chicago. The author has contributed to research in topics: Cancer & Prostate cancer. The author has an hindex of 88, co-authored 494 publications receiving 34323 citations. Previous affiliations of Walter M. Stadler include Cleveland Clinic & Northwestern University.
Papers
More filters
Journal ArticleDOI
Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial.
Toni K. Choueiri,Mayer Fishman,Bernard Escudier,Jenny J. Kim,Harriet M. Kluger,Walter M. Stadler,Jose Luis Perez-Gracia,Douglas G. McNeel,Brendan D. Curti,Michael R. Harrison,Elizabeth R. Plimack,Leonard Joseph Appleman,Lawrence Fong,Charles G. Drake,Lewis J. Cohen,Shivani Srivastava,Maria Jure-Kunkel,Quan Hong,John F. Kurland,Mario Sznol +19 more
TL;DR: Nivolumab, a fully human IgG4 programmed death-1 (PD-1) inhibitor antibody, has shown encouraging activity in mRCC and this trial assessed the immunomodulatory and clinical activity.
Journal ArticleDOI
First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70
Taofeek K. Owonikoko,Arif Hussain,Walter M. Stadler,David Smith,Harriet M. Kluger,Ana M. Molina,Parul Gulati,Aadhar Shah,Christoph Matthias Ahlers,Pina M. Cardarelli,Lewis J. Cohen +10 more
TL;DR: BMS-936561 is well tolerated over a wide range of doses in patients with advanced ccRCC and B-NHL, and the 8 mg/kg dose was the highest best tolerated dose and the recommended dose for future studies.
Journal Article
Chromosome 17-mediated dormancy of AT6.1 prostate cancer micrometastases
Marina Chekmareva,Mithra M. Kadkhodaian,Courtney M.P. Hollowell,Hyung J. Kim,Barbara A. Yoshida,Hue H. Luu,Walter M. Stadler,Carrie W. Rinker-Schaeffer +7 more
TL;DR: The findings suggest that the approximately 70-cM region of human chromosome 17 may encode a gene(s) that regulates the "dormancy" of AT6.1-17-4 micrometastases.
Journal ArticleDOI
Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (mRCC)
B. I. Rini,Daniel J. George,M.D. Michaelson,Jonathan E. Rosenberg,Ronald M. Bukowski,J. A. Sosman,Walter M. Stadler,Kim Margolin,Thomas E. Hutson,Charles M. Baum +9 more
TL;DR: Sunitinib has substantial antitumor activity in bevacizumab-refractory mRCC pts, suggesting that sunit inib may inhibit signaling pathways involved in beVacizUMab resistance.
Journal ArticleDOI
A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors
Ankit A. Desai,Richard L. Schilsky,A. Young,Linda Janisch,Walter M. Stadler,N. J. Vogelzang,S. Cadden,J. A. Wright,Mark J. Ratain +8 more
TL;DR: GTI-2040 appears to have a manageable toxicity profile and is generally well tolerated as a single agent in patients with advanced solid tumors or lymphoma.